Table 6

Cost-benefit analyses of vaccination programs in the general population
First author [Reference] Golden [[32]] Kommu [[33]] Irons [[34]]
Country Israel Barbados Caribbean
Year 1984 1998 2000
WB income group High High Upper-middle
Comparators 1. Vaccinate all 1 - 12-yr-olds 1. Rubella elimination initiative 1. Initiative to interrupt rubella transmission
2. Vaccinate pubertal girls 2. None 2. None
3. Vaccinate adult females
Perspective Societal* Payer* Payer*
Cost components measured Laboratory tests; abortions; primary care; institutional care; lost work days; NR NR
Method of cost estimation Micro-costing NR NR
Method of benefits estimation Averted costs NR NR
Time period for costs and benefits 10 years 15 years 20 years
Discounting (Rate) Yes (10%) NR NR
Results—Benefit-cost ratio 1. 1 1. 4.7 1. 13.3
2. 2 2. – 2. –
3. Negative
Stated conclusion Vaccination of children and pubertal girls is preferable The rubella elimination program using MMR was cost-beneficial The rubella elimination program using MMR was cost-beneficial
Sponsor NR NR NR

*Not explicitly reported but inferred.

WB, World Bank; NR, Not Reported; NA, Not Applicable; OP, Out Patient; CDC, US Centers for Disease Control and Prevention; LCDC, Canada Laboratory Center for Disease Control.

Babigumira et al.

Babigumira et al. BMC Public Health 2013 13:406   doi:10.1186/1471-2458-13-406

Open Data